PDCD1 and neoplasm: Biologic therapies aimed at reinvigorating anti-tumor immune responses (e.g., anti-PD-1 and anti-PD-L1 antibodies) may also positively affect Treg cells, and this phenomenon impairs the overall treatment efficacy.